It’s only fair to share… Ozoralizumab Formula C1682H2608N472O538S12 CAS 1167985-17-2 Mol weight 38434.3245 PMDA JAPAN APPROVED 2022 2022/9/26 Nanozora anti-TNFα Nanobody®; ATN-103; Nanozora; PF-5230896; TS-152 Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[1] Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm. …